Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Vaccine

• Publication date

  2007-08-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2007.05.042PMID 17655984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo

  2006cited by this paper
• Leishmania vaccines: progress and problems

  2006cited by this paper
• Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.

  2006cited by this paper
• Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.

  2006cited by this paper
• Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.

  2006cited by this paper
• Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment.

  2006cited by this paper
• Treatment of visceral leishmaniasis

  2005cited by this paper
• Second-generation vaccines against leishmaniasis.

  2005cited by this paper
• Advances in leishmaniasis.

  2005cited by this paper
• Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

  2005cited by this paper
• A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.

  2004cited by this paper
• The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development

  2004cited by this paper
• Recent advances in vaccines for leishmaniasis

  2004cited by this paper
• Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs.

  2004cited by this paper
• Leishmaniasis: current situation and new perspectives.

  2004cited by this paper
• Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

  2004cited by this paper
• Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?

  2004cited by this paper
• Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report.

  2004cited by this paper
• Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.

  2003cited by this paper
• Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine

  2003cited by this paper
• Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2.

  2003cited by this paper
• Infectivity and Virulence of Leishmania donovani Promastigotes: a Role for Media, Source, and Strain of Parasite

  2002cited by this paper
• Characterization of Leishmania donovani Antigens Encapsulated in Liposomes That Induce Protective Immunity in BALB/c Mice

  2002cited by this paper
• Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis

  2001cited by this paper
• Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.

  2001cited by this paper
• Leishmania donovani p36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis

  2001cited by this paper
• Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

  2000cited by this paper
• INDUCTION OF PARTIAL PROTECTION AGAINST LEISHMANIA DONOVANI BY PROMASTIGOTE ANTIGENS IN NEGATIVELY CHARGED LIPOSOMES

  2000cited by this paper
• A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

  2000cited by this paper
• Visceral leishmaniasis control: a public health perspective.

  2000cited by this paper
• Immunization with a Recombinant Stage-Regulated Surface Protein from Leishmania donovani Induces Protection Against Visceral Leishmaniasis1

  2000cited by this paper
• Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil.

  2000cited by this paper
• Therapy of murine cutaneous leishmaniasis by DNA vaccination.

  2000cited by this paper
• Leishmania species: models of intracellular parasitism.

  1999cited by this paper
• Neutralization of IL‐12 demonstrates the existence of discrete organ‐specific phases in the control of Leishmania donovani

  1998cited by this paper
• Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen.

  1998cited by this paper
• Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis.

  1998cited by this paper
• Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani.

  1998cited by this paper
• LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.

  1998cited by this paper
• Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens.

  1998cited by this paper
• Lipopolysaccharide-induced interleukin 8 production by human whole blood is enhanced by epinephrine and inhibited by hydrocortisone

  1997cited by this paper
• Behavior of  Visceral Leishmania donovani in an Experimentally Induced T Helper Cell 2 (Th2)-Associated Response Model

  1997cited by this paper
• Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.

  1997cited by this paper
• Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production

  1995cited by this paper
• Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein.

  1995cited by this paper
• The adjuvant effect of interleukin-12 in a vaccine against Leishmania major

  1994cited by this paper
• The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

  1994cited by this paper
• Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis

  1994cited by this paper
• Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response

  1993cited by this paper
• Mechanism and regulation of immunoglobulin isotype switching.

  1993cited by this paper
• The relationship of IL-4- and IFN gamma-producing T cells studied by lineage ablation of IL-4-producing cells.

  1993cited by this paper
• Recombinant interleukin 12 cures mice infected with Leishmania major

  1993cited by this paper
• Cytokine patterns in the pathogenesis of human leishmaniasis.

  1993cited by this paper
• Analysis of cytokine mRNA levels in interleukin‐4‐transgenic mice by quantitative polymerase chain reaction

  1992cited by this paper
• Interaction of positively-charged liposomes with blood: implications for their application in vivo.

  1991cited by this paper
• Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis.

  1991cited by this paper
• Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.

  1989cited by this paper
• Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands

  1989cited by this paper
• The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ‐dependent

  1988cited by this paper
• Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.

  1987cited by this paper
• Structure of the lipid moiety of the Leishmania donovani lipophosphoglycan.

  1987cited by this paper
• Silver staining of proteins in polyacrylamide gels.

  1981cited by this paper
• Letter: Cervical screening.

  1974cited by this paper
• Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats.

  1972cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• An Eight‐day Method for Screening Compounds against Leishmania donovani in the Golden Hamster*

  1958cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Evaluation of Leishmania homolog of activated C kinase (LACK) of Leishmania donovani in comparison to glycoprotein 63 as a vaccine candidate against visceral leishmaniasis

  2025influential citation
• Elucidation of conserved multi-epitope vaccine against Leishmania donovani using reverse vaccinology

  2023cites this paper
• Intramuscular Immunization with a Liposomal Multi-Epitope Chimeric Protein Induces Strong Cellular Immune Responses against Visceral Leishmaniasis

  2023cites this paper
• Revealing a Novel Antigen Repressor of Differentiation Kinase 2 for Diagnosis of Human Visceral Leishmaniasis in India

  2022cites this paper
• An overview on liposomal delivery and adjuvant development for leishmaniosis vaccines.

  2021cites this paper
• Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation.

  2021cites this paper
• Vaccine Design, Nanoparticle Vaccines and Biomaterial Applications

  2020cites this paper
• A phospholipase-A activity in soluble Leishmania antigens causes instability of liposomes.

  2020cites this paper
• Evaluation of Cysteine Protease C of Leishmania donovani in Comparison with Glycoprotein 63 and Elongation Factor 1α for Diagnosis of Human Visceral Leishmaniasis and for Posttreatment Follow-Up Response

  2020cites this paper
• DDX3 DEAD-box RNA helicase (Hel67) gene disruption impairs infectivity of Leishmania donovani and induces protective immunity against visceral leishmaniasis

  2020cites this paper
• Development of nano-carriers for Leishmania vaccine delivery

  2020influential citation
• Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice

  2019cites this paper
• Evaluation of Immune Response against Leishmaniasis in BALB/c Mice Immunized with Cationic DOTAP/DOPE/CHOL Liposomes Containing Soluble Leishmania major Antigens

  2019cites this paper
• Investigation of the antigenicity and protective efficacy of Leishmania promastigote membrane antigens in search of potential diagnostic and vaccine candidates against visceral leishmaniasis

  2019cites this paper
• Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments

  2019cites this paper
• Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis.

  2019cites this paper
• S0031182017001731jra 740..751

  2018cites this paper
• Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis

  2018cites this paper
• ASP49‐phospholipase A2‐loaded liposomes as experimental therapy in cutaneous leishmaniasis model

  2018cites this paper
• Evaluation of Lsa46 and Lsa77 Leptospiral Proteins for Their Immunoprotective Activities in Hamster Model of Leptospirosis

  2018cites this paper
• Drug Resistance in Leishmania Parasites

  2018cites this paper
• The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome

  2018cites this paper
• DDA/TDB liposomes containing soluble Leishmania major antigens induced a mixed Th1/Th2 immune response in BALB/c mice

  2017cites this paper
• Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN-γ and IL-12 mediated immune responses in Leishmania donovani infected hamsters.

  2017cites this paper
• Immune response and protective profile elicited by a multi-epitope chimeric protein derived from Leptospira interrogans.

  2017cites this paper
• Total Leishmania antigens with Poly(I:C) induce Th1 protective response

  2017cites this paper
• Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis

  2017cites this paper
• Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis

  2017cites this paper
• Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines

  2017cites this paper
• Liposomal adjuvant development for leishmaniasis vaccines

  2017cites this paper
• Management of visceral leishmaniasis with therapeutic vaccines

  2016cites this paper
• Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.

  2016cites this paper
• Delivery systems for Leishmania vaccine development

  2016cites this paper
• Immunoprotective responses of T helper type 1 stimulatory protein‐S‐adenosyl‐L‐homocysteine hydrolase against experimental visceral leishmaniasis

  2016cites this paper
• Nanobiotechnologic approach to a promising vaccine prototype for immunisation against leishmaniasis: a fast and effective method to incorporate GPI-anchored proteins of Leishmania amazonensis into liposomes

  2015cites this paper
• Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation.

  2015cites this paper
• Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review

  2015cites this paper
• Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.

  2015cites this paper
• Combining Cationic Liposomal Delivery with MPL-TDM for Cysteine Protease Cocktail Vaccination against Leishmania donovani : Evidence for Antigen Synergy and Protection

  2014cites this paper
• Visceral Leishmaniasis: Immune Mechanisms and New Insights in Vaccine Development and Control

  2014cites this paper
• Immunological consequences of stress-related proteins – cytosolic tryparedoxin peroxidase and chaperonin TCP20 – identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis

  2014cites this paper
• Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.

  2014cites this paper
• Evaluation of the immunogenicity and protective efficacy of Killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis

  2014cites this paper
• Combination of Liposomal CpG Oligodeoxynucleotide 2006 and Miltefosine Induces Strong Cell-Mediated Immunity during Experimental Visceral Leishmaniasis

  2014cites this paper
• Nucleosomal Histone Proteins of L. donovani: A Combination of Recombinant H2A, H2B, H3 and H4 Proteins Were Highly Immunogenic and Offered Optimum Prophylactic Efficacy against Leishmania Challenge in Hamsters

  2014cites this paper
• Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis

  2014cites this paper
• IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine

  2014cites this paper
• Th1 Stimulatory Proteins of Leishmania donovani: Comparative Cellular and Protective Responses of rTriose Phosphate Isomerase, rProtein Disulfide Isomerase and rElongation Factor-2 in Combination with rHSP70 against Visceral Leishmaniasis

  2014cites this paper
• The role of surface charge of ISCOMATRIX nanoparticles on the type of immune response generated against Leishmaniasis in BALB/c mice

  2014cites this paper
• Dynamicity of Immune Regulation during Visceral Leishmaniasis

  2014cites this paper
• Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice

  2013cites this paper
• Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).

  2013cites this paper
• Vaccination as a Control Measure

  2013cites this paper
• Radio-attenuated leishmanial parasites as immunoprophylactic agent against experimental murine visceral leishmaniasis.

  2012cites this paper
• Leishmania donovani: Immunostimulatory Cellular Responses of Membrane and Soluble Protein Fractions of Splenic Amastigotes in Cured Patient and Hamsters

  2012cites this paper
• Leishmania donovani Triose Phosphate Isomerase: A Potential Vaccine Target against Visceral Leishmaniasis

  2012cites this paper
• Effect of NF-κB Inhibitor Aurothiomalate on Local Inflammation in Experimental Th1- and Th2-Type Immune Response

  2012cites this paper
• Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis

  2012cites this paper
• Evaluation of Leishmania donovani Protein Disulfide Isomerase as a Potential Immunogenic Protein/Vaccine Candidate against Visceral Leishmaniasis

  2012cites this paper
• Proteoliposomes in nanobiotechnology

  2012cites this paper
• Comparison of Liposome-Polycation-DNA(LPD) and Monophosphoryl Lipid A(MPL) Adjuvant Formulations in BALB/c Mice Models

  2012cites this paper
• Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.

  2012cites this paper
• Secreted virulence factors and immune evasion in visceral leishmaniasis

  2012cites this paper
• Heat shock proteins enriched-promastigotes of Leishmania major inducing Th2 immune response in BALB/c mice.

  2012cites this paper
• Biological targeting and drug delivery in control of Leishmaniasis

  2012cites this paper
• Vaccine Development Against Leishmania donovani

  2012cites this paper
• Challenge Leishmania Protects Hamsters against-Infected Patients / Hamsters and Leishmania and IL-12 Response in Cured γ Strong IFN-, Generates Leishmania donovani Protein of Elongation Factor-2 , a Th 1 Stimulatory

  2011cites this paper
• Elongation Factor-2, a Th1 Stimulatory Protein of Leishmania donovani, Generates Strong IFN-γ and IL-12 Response in Cured Leishmania-Infected Patients/Hamsters and Protects Hamsters against Leishmania Challenge

  2011cites this paper
• Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis.

  2011cites this paper
• Development of Vaccines against Visceral Leishmaniasis

  2011cites this paper
• Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN

  2011cites this paper
• Immunity to Visceral Leishmaniasis

  2011cites this paper
• Intranasal immunization with LACK-DNA promotes protective immunity in hamsters challenged with Leishmania chagasi

  2011influential citation
• Leishmania Exosomes Modulate Innate and Adaptive Immune Responses through Effects on Monocytes and Dendritic Cells

  2010cites this paper
• Identification of a novel secretion system in Leishmania : composition, mechanisms, and immune modulating properties

  2010cites this paper
• Monocytes and Dendritic Cells Responses through Effects on Innate and Adaptive Immune Leishmania Exosomes Modulate

  2010cites this paper
• Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.

  2010cites this paper
• Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.

  2010cites this paper
• Retro-engineering of liposomal vaccine adjuvants: role of a microarray-based screen.

  2010cites this paper
• Immunization with the DNA-Encoding N-Terminal Domain of Proteophosphoglycan of Leishmania donovani Generates Th1-Type Immunoprotective Response against Experimental Visceral Leishmaniasis1

  2009cites this paper
• DELIVERY SYSTEMS FOR THE TREATMENT AND PREVENTION OF LEISHMANIASIS

  2009cites this paper
• Lipid microspheres loaded with antigenic membrane proteins of the Leishmania amazonensis as a potential biotechnology application.

  2009cites this paper
• The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).

  2009cites this paper
• Visceral Leishmaniasis Immunoprotective Response against Generates Th 1-Type Leishmania donovani of N-Terminal Domain of Proteophosphoglycan Immunization with the DNA-Encoding

  2009cites this paper
• Identification of Novel Leishmania donovani Antigens that Help Define Correlates of Vaccine-Mediated Protection in Visceral Leishmaniasis

  2009cites this paper
• Vaccination Route That Induces Transforming Growth Factor β Production Fails To Elicit Protective Immunity against Leishmania donovani Infection

  2009cites this paper
• Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis

  2009cites this paper
• Vaccine Trail against Trypanosomia evansi

  2009cites this paper
• Recent developments in leishmaniasis vaccine delivery systems

  2008influential citation
• Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.

  2008influential citation
• The utility of rhesus monkey (Macaca mulatta) and other non-human primate models for preclinical testing of Leishmania candidate vaccines.

  2008cites this paper
• Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.

  2008cites this paper
• h 1-stimulatory polyproteins of soluble Leishmania donovani promastigotes anging from 89 . 9 to 97 . 1 kDa offers long-lasting protection against xperimental visceral leishmaniasis

  2008cites this paper
• Old targets and new beginnings: a multifaceted approach to combating Leishmaniasis, a neglected tropical disease

  2007cites this paper
• Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.

  2007cites this paper
• On Monocytes and Dendritic Cells Adaptive Immune Responses through Effects Leishmania Exosomes Modulate Innate And

  year unknowncites this paper